Having trouble accessing articles? Reset your cache.

Mipomersen: Phase III data

A double-blind, U.S. and Canadian Phase III trial in 158 patients with hypercholesterolemia and at high risk of developing coronary heart disease (CHD) showed that once-weekly subcutaneous injections of 200 mg

Read the full 319 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE